Stoke Therapeutics, Inc. (Nasdaq: STOK) has announced the pricing of its upsized underwritten public offering of common stock, aiming to raise $125 million. The company will offer 5,555,557 shares of its common stock at $13.50 per share, alongside pre-funded warrants to purchase up to 3,703,730 shares of its common stock. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. The proceeds will be used to fund research, clinical development, manufacturing, and general corporate purposes. The offering is expected to close in early April, subject to customary conditions. Stoke Therapeutics is known for its innovative approach to addressing severe diseases through RNA-based medicines.
Stoke Therapeutics Prices Upsized Public Offering at $13.50 Per Share
Date:
Updated: [falahcoin_post_modified_date]